Philip Nadeau is a managing director and senior research analyst on the biotechnology team at Cowen. He joined Cowen in 2000 and is responsible for covering approximately 25 large-, mid-, and small-cap biotechnology stocks. Cowen’s biotechnology team has consistently been among the top-ranked teams in the Greenwich Survey. Dr. Nadeau has been recognized in The Wall Street Journal’s “Best on the Street” rankings and in the Institutional Investor poll. His views on biotechnology topics are often quoted by national news services such as Reuters, Bloomberg and the Dow Jones newswires. Prior to joining Cowen, he was a research assistant at Children’s Hospital, Boston.
Dr. Nadeau has an SB/MEng in electrical engineering and computer science from MIT and a Ph.D. in Neurobiology from Harvard University.